Glioblastoma, IDH-Wildtype — Trials

Glioblastoma, IDH-Wildtype — Trials · CancerIndex

Clinical trials

Registered studies

303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 42
Ph III recruiting: 3
Growth YoY: —
Industry share: 12%
Top sponsor: Mayo Clinic
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (64)

clinicaltrialsPublishedShowing 1–34 of 34 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05864534	Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma	active not recruiting	Phase 2	25	Northwestern UniversityOTHER	1	Sep 29, 2026	clinicaltrials
NCT05432804	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	recruiting	Phase 1 / Phase 2	97	National Cancer Institute (NCI)NIH	1	Sep 28, 2026